04693116001
Roche
cOmplete™ Protease Inhibitor Cocktail
Tablets provided in EASYpacks
Synonym(s):
protease inhibitor
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352204
NACRES:
NA.21
Recommended Products
form
tablet
packaging
pkg of 20 tablets
manufacturer/tradename
Roche
solubility
water: soluble
absorption
0.08 at 280 nm
storage temp.
2-8°C
Related Categories
General description
cOmplete Protease Inhibitor Tablets inhibit a broad spectrum of serine, cysteine, and metalloproteases, as well as calpains. Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete tablets contain EDTA and both irreversible and reversible protease inhibitors. Protease inhibitors present in cOmplete Tablets do not form irreversible complexes with the SH groups of proteins.
cOmplete tablets contain EDTA and both irreversible and reversible protease inhibitors. Protease inhibitors present in cOmplete Tablets do not form irreversible complexes with the SH groups of proteins.
Specificity
Inhibits a broad spectrum of serine proteases, cysteine proteases, and metalloproteases, as well as calpains.
Application
cOmplete™ Protease Inhibitor Cocktail has been used as an component in
- extraction buffer for protein extraction from Arabidopsis seedling
- in radioimmunoprecipitation assay (RIPA) buffer for the isolation of protein from lymphocytes
- the extraction buffer for the lysis of protoplast.
cOmplete™ is used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
cOmplete contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete contains EDTA (1 tablet yields a 1 mM EDTA solution in 50 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography. Alternatively, the product cOmplete, EDTA-free, can be used. These tablets are identical to cOmplete, with the exception that no EDTA or other chelating agent is present.
cOmplete Tablets inhibit proteolytic activity in large extraction volumes (up to 50 ml). If you are working with smaller volumes (up to 10 ml), we recommend to use cOmplete, Mini. The composition of the cOmplete, Mini Tablet, is identical to the normal cOmplete Tablet.
cOmplete contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete contains EDTA (1 tablet yields a 1 mM EDTA solution in 50 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography. Alternatively, the product cOmplete, EDTA-free, can be used. These tablets are identical to cOmplete, with the exception that no EDTA or other chelating agent is present.
cOmplete Tablets inhibit proteolytic activity in large extraction volumes (up to 50 ml). If you are working with smaller volumes (up to 10 ml), we recommend to use cOmplete, Mini. The composition of the cOmplete, Mini Tablet, is identical to the normal cOmplete Tablet.
Features and Benefits
Use cOmplete Protease Inhibitor Tablets to protect your proteins from a wide range of proteases. In just minutes, uninhibited proteolytic activity can degrade the protein you have spent days isolating. Each of these convenient water-soluble tablets contains a blend of protease inhibitors that inhibits proteolytic activity from most cell types, including animals, plants, yeast, and bacteria. No weighing or measuring is necessary, ensuring consistent results.
- Convenience: Simply push the quick-dissolving tablet through the foil packaging of the EASYpack into your buffer.
- Complete protection: Instantly protect your proteins against a broad range of proteases.
- Flexible: Protect proteins in extracts from almost any tissue or cell, including animals, plants, yeast, bacteria, or fungi.
- Safe: Choose non-toxic inhibitors that pose no risk to you or those around you.
Packaging
20 individually packed cOmplete Protease Inhibitor Cocktail Tablets in foil blisters.
Components
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Physical form
Tablets in foil blister packs
Preparation Note
Working concentration: 1 tablet per 50ml extraction solution
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not finger nail) to prevent the breakage of tablets.
Preparation of Working Solution
One cOmplete tablet is sufficient for the inhibition of the proteolytic activity in 50ml extraction solution. When a very high proteolytic activity is present, one tablet should be used for 25ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (25 X conc.) can be prepared.
Preparation of Stock solution (25 X conc.)
Dissolve one cOmplete tablet in 2ml dist. water or in 2ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8°C for 1 to 2 weeks, or at least 12 weeks at -15 to -25°C.
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not finger nail) to prevent the breakage of tablets.
Preparation of Working Solution
One cOmplete tablet is sufficient for the inhibition of the proteolytic activity in 50ml extraction solution. When a very high proteolytic activity is present, one tablet should be used for 25ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (25 X conc.) can be prepared.
Preparation of Stock solution (25 X conc.)
Dissolve one cOmplete tablet in 2ml dist. water or in 2ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8°C for 1 to 2 weeks, or at least 12 weeks at -15 to -25°C.
Reconstitution
Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 25x stock solutions in 2 ml water or 100 mM phosphate buffer, pH 7.0. Stock solution is stable for 1-2 weeks at 2 to 8 °C or at least 12 weeks at -15 to -25 °C; can be used in thiol-containing solutions at 15 to 25 °C.
Storage and Stability
Store at 2 to 8 °C. (storage at -15 to -25 °C is also possible)
Legal Information
cOmplete is a trademark of Roche
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Skin Corr. 1B
Storage Class
8A - Combustible, corrosive hazardous materials
wgk_germany
WGK 2
flash_point_f
does not flash
flash_point_c
does not flash
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Yuying Zhao et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 32(9), e13895-e13895 (2020-06-10)
Hirschsprung's disease (HSCR) is a congenital gastrointestinal disorder, characterized by enteric ganglia absence in part or entire of the colon, due to abnormal colonization and migration of enteric neural crest cells (ENCCs) during development. Currently, besides surgery which is the
Sinead Toomey et al.
Journal of translational medicine, 18(1), 99-99 (2020-02-24)
An increasing number of anti-cancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Successful use of these therapies is dependent on the presence or absence of somatic mutations within the patient's tumor that can
Comparative study on the response of rat primary astrocytes and microglia to methylmercury toxicity.
Mingwei Ni et al.
Glia, 59(5), 810-820 (2011-02-26)
As the two major glial cell types in the brain, astrocytes and microglia play pivotal but different roles in maintaining optimal brain function. Although both cell types have been implicated as major targets of methylmercury (MeHg), their sensitivities and adaptive
Yanke Chen et al.
Nature cell biology, 22(10), 1276-1285 (2020-10-03)
Breast cancer brain metastasis (BCBM) is a devastating disease. Radiation therapy remains the mainstay for treatment of this disease. Unfortunately, its efficacy is limited by the dose that can be safely applied. One promising approach to overcoming this limitation is
EL1-like casein kinases suppress ABA signaling and responses by phosphorylating and destabilizing the ABA receptors PYR/PYLs in Arabidopsis
Chen HH, et al.
Molecular plant, 11(5), 706-719 (2018)
Related Content
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service